- Home
- CRDO vs ROIV Comparison
CRDO vs ROIV Comparison
Compare CRDO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRDO | ROIV |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | Cayman Islands | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2B | 14.1B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRDO | ROIV |
|---|---|---|
| Price | $140.35 | $23.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $179.91 | $24.31 |
| AVG Volume (30 Days) | ★ 7.5M | 7.4M |
| Earning Date | 12-01-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $796,128,000.00 | $20,329,000.00 |
| Revenue This Year | $127.02 | N/A |
| Revenue Next Year | $28.18 | $376.94 |
| P/E Ratio | $126.25 | ★ N/A |
| Revenue Growth | ★ 224.17 | N/A |
| 52 Week Low | $29.09 | $8.73 |
| 52 Week High | $213.80 | $23.23 |
Technical Indicators
Market Signals| Indicator | CRDO | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 71.09 |
| Support Level | $176.00 | $20.14 |
| Resistance Level | $213.80 | $21.48 |
| Average True Range (ATR) | 12.15 | 0.77 |
| MACD | -3.98 | 0.09 |
| Stochastic Oscillator | 4.20 | 88.97 |
Price Performance
Historical ComparisonAbout CRDO Credo Technology Group Holding Ltd
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.